Key Details
Annual ROE
-61.02%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 29, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 19, 2023Analyst ratings
Recent major analysts updates
09 May '23 Mizuho
Neutral03 Jan '23 Guggenheim
Neutral16 Nov '22 HC Wainwright & Co.
Neutral15 Nov '22 Stifel
Hold15 Nov '22 Mizuho
Neutral15 Nov '22 Guggenheim
Neutral15 Nov '22 Canaccord Genuity
Hold12 Sept '22 HC Wainwright & Co.
Buy12 Sept '22 B of A Securities
Underperform02 Mar '22 Piper Sandler
OverweightScreeners with NLTX included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Neoleukin Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
NLTX
GuruFocus27 July 2023
San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Financial), a biopharmaceutical company based in the USA. This article provides an in-depth analysis of the transaction, the profiles of both Redmile Group and Neoleukin Therapeutics, and an evaluation of the latter's financial health and industry position.
Neoleukin Therapeutics: Strategic Review Play
NLTX
Seeking Alpha19 April 2023
Neoleukin Therapeutics: Strategic Review Play
FAQ
- What is the primary business of Neoleukin Therapeutics?
- What is the ticker symbol for Neoleukin Therapeutics?
- Does Neoleukin Therapeutics pay dividends?
- What sector is Neoleukin Therapeutics in?
- What industry is Neoleukin Therapeutics in?
- What country is Neoleukin Therapeutics based in?
- When did Neoleukin Therapeutics go public?
- Is Neoleukin Therapeutics in the S&P 500?
- Is Neoleukin Therapeutics in the NASDAQ 100?
- Is Neoleukin Therapeutics in the Dow Jones?
- When was Neoleukin Therapeutics's last earnings report?
- When does Neoleukin Therapeutics report earnings?
- Should I buy Neoleukin Therapeutics stock now?
What is the primary business of Neoleukin Therapeutics?
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
What is the ticker symbol for Neoleukin Therapeutics?
The ticker symbol for Neoleukin Therapeutics is NASDAQ:NLTX
Does Neoleukin Therapeutics pay dividends?
No, Neoleukin Therapeutics does not pay dividends
What sector is Neoleukin Therapeutics in?
Neoleukin Therapeutics is in the Healthcare sector
What industry is Neoleukin Therapeutics in?
Neoleukin Therapeutics is in the Biotechnology industry
What country is Neoleukin Therapeutics based in?
Neoleukin Therapeutics is headquartered in United States
When did Neoleukin Therapeutics go public?
Neoleukin Therapeutics's initial public offering (IPO) was on 07 March 2014
Is Neoleukin Therapeutics in the S&P 500?
No, Neoleukin Therapeutics is not included in the S&P 500 index
Is Neoleukin Therapeutics in the NASDAQ 100?
No, Neoleukin Therapeutics is not included in the NASDAQ 100 index
Is Neoleukin Therapeutics in the Dow Jones?
No, Neoleukin Therapeutics is not included in the Dow Jones index
When was Neoleukin Therapeutics's last earnings report?
Neoleukin Therapeutics's most recent earnings report was on 29 February 2024
When does Neoleukin Therapeutics report earnings?
The date for Neoleukin Therapeutics's next earnings report has not been announced yet
Should I buy Neoleukin Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions